Stryker Corporation (SYK)
Stryker is a global medical technology giant that makes the surgical tools, implants, and hospital equipment used by doctors to help patients recover.
Is Stryker Corporation a good stock for a UK beginner?
The honest version: Stryker is a global medical technology giant that makes the surgical tools, implants, and hospital equipment used by doctors to help patients recover.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Stryker becomes the dominant provider for integrated hospital digital systems.
Major regulatory changes or product recalls damage the brand.
What does Stryker Corporation do?
Stryker makes everything from artificial hips and knees to the high-tech beds and stretchers you see in hospitals. Money flows in from selling these essential tools to healthcare providers who need reliable equipment for surgery and patient care. The question that matters most is whether they can keep growing profits even as hospitals tighten their budgets.
On our factor screen it looks strongest on quality and growth, and weakest on momentum.
- ✓Pays a dividend - about 1.1% a year
- ✓Growing - revenue up about 9% over the year
- !High P/E of 38 - big growth is already priced in
- ✓Strong return on shareholder money (ROE 17%)
- High profit margins show they have strong control over their costs.
- Essential products mean demand is less likely to disappear during tough economic times.
- A long history of being a trusted partner to hospitals worldwide.
- Changes in government healthcare policies could impact how much hospitals can spend.
- Product recalls or safety issues could lead to expensive legal costs and reputational damage.
- Reliance on a steady stream of elective surgeries which can be postponed.
What do Stryker Corporation's numbers mean?
How much money does Stryker Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Stryker Corporation pay a dividend?
Yes - Stryker Corporation currently pays a dividend of about 1.1% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does Stryker Corporation report earnings, and how did recent quarters go?
Stryker Corporation is next scheduled to report on about 2026-10-29 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $3.49 | $3.69 | Beat +6% |
| 2026-04-30 | $2.98 | $2.60 | Missed -13% |
| 2026-01-29 | $4.40 | $4.47 | Beat +2% |
| 2025-10-30 | $3.13 | $3.19 | Beat +2% |
| 2025-07-31 | $3.07 | $3.13 | Beat +2% |
| 2025-05-01 | $2.73 | $2.84 | Beat +4% |
Across the last 6 quarters here, Stryker Corporation came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Stryker Corporation?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Stryker Corporation?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High profit margins show they have strong control over their costs.
- Essential products mean demand is less likely to disappear during tough economic times.
- A long history of being a trusted partner to hospitals worldwide.
- The current share price is high relative to recent earnings.
- Revenue growth has been relatively slow recently.
- The medical device market is highly competitive and sensitive to pricing pressure.
- Changes in government healthcare policies could impact how much hospitals can spend.
- Product recalls or safety issues could lead to expensive legal costs and reputational damage.
- Reliance on a steady stream of elective surgeries which can be postponed.
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained drop in the number of elective surgeries performed globally.
- A significant loss of market share to cheaper, generic medical device manufacturers.
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.